# VERV — slm-full-cpu

## Metadata

ticker: VERV
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: 459e5c2f23488f041cab961431cf43a197a44cf6db3d18ca05a35378ced22b5f
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 686, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 205.376, "latency_s_total": 205.376, "parse_failure": 0, "prompt_tokens": 2651, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 456, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 163.038, "latency_s_total": 163.038, "parse_failure": 0, "prompt_tokens": 2399, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 145, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 65.537, "latency_s_total": 65.537, "parse_failure": 0, "prompt_tokens": 616, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 145, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 84.705, "latency_s_total": 84.705, "parse_failure": 0, "prompt_tokens": 610, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 201, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 93.939, "latency_s_total": 93.939, "parse_failure": 0, "prompt_tokens": 525, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 181, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 93.219, "latency_s_total": 93.219, "parse_failure": 0, "prompt_tokens": 763, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 1003, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 118.651, "latency_s_total": 118.651, "parse_failure": 0, "prompt_tokens": 1716, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "VERV",
  "company_name": "N/A",
  "currency": "USD"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2025-02-27",
    "summary": "Item 1A. Risk Factors. Our future operating results could differ materially from the results described in this Annual Report on Form 10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See p"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2025-05-14",
    "summary": "Item 1A. Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 91 Item 5. Other Information 91 Item 6. Exhibits 92 Signatures 93 Part I \u2500 Financi al Information Item 1. Financi al Statements Verve Therapeutics, Inc. Condensed consolidat ed balance sheets (in thousands, except share and per share amounts) (unaudited) March 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 96,554 $ 172,560 Marketable securities 400,523 351,721 Collaboration receivable 1,399 3,255 Prepaid expenses and other current assets 13,174 15,215 Total current assets 511,650 542,751 Property and equipment, net 18,457 18,644 Restricted cash 4,774 4,774 Operating lease right-of-use assets 76,217 78,082 Other long term assets 3,065 3,141 Total assets $ 614,163 $ 647"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided risk factors from the Annual Report on Form 10-K for VERV, the key takeaways regarding the company's financial position and operational outlook are as follows:

**Financial Performance and Losses**
*   **Significant Operating Losses:** The company has incurred substantial net losses since inception, reporting $198.7 million for the year ended December 31, 2024, $200.1 million for 2023, and $157.4 million for 2022.
*   **Accumulated Deficit:** As of December 31, 2024, the company had an accumulated deficit of $743.0 million.
*   **No Revenue:** The company has no approved products and has not generated any revenue from product sales. It expects to incur significant operating expenses and net losses for the foreseeable future, with potential fluctuations from quarter to quarter.

**Funding and Capital Resources**
*   **Current Liquidity:** As of December 31, 2024, the company held $524.3 million in cash, cash equivalents, and marketable securities. Additionally, in February 2025, the company received a $20.0 million milestone payment from Eli Lilly and Company (Lilly) under the Lp(a) program.
*   **Funding Horizon:** Management estimates that existing resources will fund operating expenses and capital expenditures into mid-2027. However, this estimate is based on assumptions that may prove incorrect, and the company could deplete resources sooner than expected.
*   **Need for Additional Capital:** The company currently has no credit facility or committed sources of capital. If unable to raise sufficient funds on acceptable terms, the company may be forced to delay, limit, reduce, or terminate research and development programs or commercialization efforts.

**Operational Expenses and Drivers**
*   **Increasing Costs:** Expenses are expected to increase substantially due to ongoing and planned clinical trials, including the Heart-2 Phase 1b trial of VERVE-102, the Pulse-1 Phase 1b trial of VERVE-201, and a planned Phase 2 clinical trial for the PCSK9 program. Other cost drivers include preclinical development, intellectual property maintenance, regulatory approvals, and potential milestone payments to partners such as Lilly, Acuitas Therapeutics, The Broad Institute, Harvard, and Novartis.
*   **Commercialization Costs:** If marketing approval is obtained, the company expects to incur significant costs related to manufacturing, sales, marketing, and distribution, as well as post-approval requirements like cardiovascular outcomes trials (CVOT).

**Strategic Risks**
*   **Uncertainty of Success:** Identifying and developing product candidates is time-consuming, expensive, and uncertain. There is no assurance that the company will obtain marketing approval or achieve commercial success.
*   **Market and Regulatory Risks:** The company faces risks related to regulatory delays, third-party intellectual property challenges, and disruptions in global financial markets that could impact its ability to access capital.
*   **Management Distraction:** Additional fundraising efforts may divert management’s attention from day-to-day activities, potentially adversely affecting the development and commercialization of product candidates.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Capital:** The company has incurred significant losses since inception, with net losses of $198.7 million, $200.1 million, and $157.4 million for the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the accumulated deficit was $743.0 million. The company has no approved products, has generated no revenue from product sales, and expects to incur losses for the foreseeable future.
*   **Operational and Development Risks:** The company has no products approved for sale and has not yet completed a clinical trial of any product candidate. The pharmaceutical product development process is time-consuming, expensive, and uncertain, with no assurance that product candidates will receive marketing approval or achieve commercial success.
*   **Substantial Funding Requirements:** The company expects to incur substantial additional research and development, commercialization, and public company operating expenses. It currently has no credit facility or committed sources of capital. If unable to raise capital on acceptable terms, the company may be forced to delay, reduce, or eliminate product development programs or commercialization efforts.
*   **Revenue Uncertainty:** Even if products are approved, revenue depends on market size, pricing, reimbursement, and commercial rights. There is no assurance that revenues will be significant enough to achieve profitability.
*   **Capital Resource Depletion:** Although the company had $524.3 million in cash, cash equivalents, and marketable securities as of December 31, 2024, and received a $20.0 million milestone payment in February 2025, these resources are estimated to fund operations only into mid-2027. This estimate is based on assumptions that may prove incorrect, potentially forcing the company to seek additional funding sooner than planned.
*   **External Factors:** Disruption in global financial markets could reduce the ability to access capital. Additionally, fundraising efforts may divert management from day-to-day activities, adversely affecting the ability to develop and commercialize product candidates.

## Pre-written sections (judge input)

### Financial Health

Specific price, market cap, P/E ratio, revenue, and profit margin data are not available in the provided source material. However, the company’s balance sheet indicates a strong liquidity position, with cash and cash equivalents decreasing from $172.6 million to $96.6 million, while marketable securities increased to $400.5 million as of March 31, 2025. Total assets stand at $614.2 million, reflecting a slight decline from $647.0 million at the end of 2024, likely due to operational expenditures. The firm maintains substantial liquid resources to support ongoing operations and development activities.

### Recent Developments

As of the latest reporting period, there are no specific recent news events or material corporate announcements to report for Verve Therapeutics. The company’s most significant recent activity involves the filing of its Form 10-Q for the quarter ended March 31, 2025, which highlights a reduction in cash and cash equivalents to $96.6 million from $172.6 million at the end of 2024. This decrease in liquidity, alongside a rise in marketable securities, suggests ongoing operational expenditures or strategic investments without corresponding new capital raises. Investors should monitor upcoming filings for updates on cash burn rates and potential financing needs given the tightened balance sheet.

### SEC Filing Highlights
VERV reported a net loss of $198.7 million for 2024, maintaining its accumulated deficit at $743.0 million as the company continues to generate no revenue from product sales. The firm holds $524.3 million in cash and marketable securities as of year-end, supplemented by a $20.0 million milestone payment from Eli Lilly in February 2025. Management estimates these resources will fund operations through mid-2027, though this timeline relies on assumptions that may prove incorrect. Significant future expenses are anticipated to drive continued losses, stemming from ongoing clinical trials for VERVE-102 and VERVE-201, as well as potential commercialization costs. The company currently lacks committed capital sources and may need to raise additional funds to sustain its research and development programs.

### Risk Factors

*   **Substantial Financial Losses and Capital Depletion:** The company has incurred significant net losses since inception and has no approved products or revenue from sales. While it holds approximately $524.3 million in cash and equivalents, these resources are projected to fund operations only through mid-2027, creating a risk of capital exhaustion before achieving profitability.
*   **High-Risk Product Development and Regulatory Uncertainty:** The company has not yet completed any clinical trials and has no products approved for sale. The pharmaceutical development process is expensive and uncertain, with no assurance that product candidates will receive marketing approval or achieve commercial success.
*   **Dependence on External Financing:** The company has no committed sources of capital and expects to incur substantial additional R&D and operating expenses. Inability to raise capital on acceptable terms, potentially exacerbated by global financial market disruptions, could force the company to delay, reduce, or eliminate its product development and commercialization efforts.

## Audited (Exec Summary + Outlook)

### Executive Summary
Verve Therapeutics is a clinical-stage biotechnology company focused on developing in vivo gene-editing therapies, currently managing a balance sheet with $524.3 million in cash and marketable securities as of year-end 2024. The investment case is notable due to the company’s reliance on a $20.0 million milestone payment from Eli Lilly and its runway extending only through mid-2027, highlighting the critical need for continued capital efficiency. The single most important near-term variable is the successful execution of ongoing clinical trials for VERVE-102 and VERVE-201, which will determine whether the firm can secure further external financing or achieve regulatory milestones before its current liquidity is exhausted.

### Outlook
The directional outlook for Verve Therapeutics is cautiously constructive, anchored by its robust liquidity position but tempered by the inherent binary risks of pre-commercial gene editing. Key variables to monitor include the clinical data readouts for VERVE-102 and VERVE-201, as well as the company’s ability to manage its cash burn rate to preserve the mid-2027 runway. The thesis would be strengthened by positive efficacy signals that validate the in vivo editing platform and facilitate strategic partnerships or favorable financing terms; conversely, the view would weaken significantly if clinical progress stalls or if the company faces difficulties raising additional capital in a challenging market environment, potentially forcing a dilutive raise or strategic pivot before commercialization.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically identify every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the Executive Summary and Outlook sections, then evaluate each against the source data.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "$524.3 million in cash and marketable securities as of year-end 2024"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both explicitly state "the company had $524.3 million in cash, cash equivalents, and marketable securities as of December 31, 2024," and the SEC Filing Highlights pre-written section repeats this figure for year-end.

---

CLAIM: "$20.0 million milestone payment from Eli Lilly"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "in February 2025, the company received a $20.0 million milestone payment from Eli Lilly and Company (Lilly) under the Lp(a) program," and this is confirmed in the SEC Filing Highlights pre-written section.

---

CLAIM: "runway extending only through mid-2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights states "Management estimates that existing resources will fund operating expenses and capital expenditures into mid-2027," confirmed in both RAG Risk Factors and the SEC Filing Highlights pre-written section.

---

CLAIM: "ongoing clinical trials for VERVE-102 and VERVE-201"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly names "the Heart-2 Phase 1b trial of VERVE-102" and "the Pulse-1 Phase 1b trial of VERVE-201" as ongoing clinical trials, and the SEC Filing Highlights pre-written section references both programs.

---

**OUTLOOK**

---

CLAIM: "mid-2027 runway"
LABEL: SUPPORTED
REASON: Directly stated in the RAG SEC Highlights and RAG Risk Factors: "Management estimates that existing resources will fund operating expenses and capital expenditures into mid-2027."

---

CLAIM: "clinical data readouts for VERVE-102 and VERVE-201"
LABEL: SUPPORTED
REASON: Both VERVE-102 and VERVE-201 are named as active clinical programs in the RAG SEC Highlights and SEC Filing Highlights pre-written section; monitoring their data readouts is a direct forward-looking reference to these named programs, which are present in the source data.

---

**SUMMARY NOTE**

No price targets, P/E ratios, revenue figures, percentage metrics, or other quantitative forward-looking numbers appear in the Outlook section beyond the mid-2027 runway reference already evaluated. All quantitative and named-milestone claims in both sections are accounted for above. No claims are found to be UNSUPPORTED or INFERENCE.
